Yuan Yuan
Medical Oncology · Pasadena, CANPI 1073664660
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $327,463 of the $509,683 with a category attached, or 64.2%. 25 manufacturers reported payments, led by AstraZeneca at 30.1% of the total. Reporting peaked in 2022 at $196,385 and has fallen 91.1% since, to $17,469 in 2025. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $1317.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$153K
- Gilead$136K
- Daiichi Sankyo Inc.$59K
- Eisai Inc.$35K
- Novartis$35K
- Genentech USA, Inc.$33K
- plus $58K from 19 others
Across 250 payments — averaging $36,074 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.8M
- Merck$3.4M
- Daiichi Sankyo Inc.$596K
- AstraZeneca$487K
- Eisai Inc.$206K
- Genentech, Inc.$147K
- plus $347K from 8 others
What the payments were for
- Consulting fees$130,01126%
- Speaking & faculty fees$327,46364%
- Travel & lodging$40,9778%
- Food & beverage$11,0992%
- Education$1330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 105 | $153,185 |
| Gilead | 83 | $135,690 |
| Daiichi Sankyo Inc. | 52 | $59,290 |
| Eisai Inc. | 31 | $35,425 |
| Novartis | 26 | $34,529 |
| Genentech USA, Inc. | 29 | $33,129 |
| Merck | 16 | $19,453 |
| Pfizer | 12 | $16,407 |
| AbbVie | 12 | $4,817 |
| Seagen Inc. | 2 | $4,680 |
| Genentech, Inc. | 1 | $3,300 |
| Stemline Therapeutics Inc. | 3 | $2,584 |
| Sanofi | 1 | $2,552 |
| Macrogenics, Inc. | 1 | $1,500 |
| Immunomedics, Inc. | 1 | $1,375 |
| Tersera Therapeutics LLC | 1 | $1,078 |
| Athenex Pharmaceutical Division, LLC | 1 | $175 |
| Beigene USA, Inc. | 1 | $141 |
| Amgen | 3 | $136 |
| Biontech SE | 1 | $81 |
| Puma Biotechnology, Inc. | 1 | $52 |
| Therakos LLC | 1 | $37 |
| Tempus AI, Inc | 1 | $26 |
| GE HealthCare | 1 | $25 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$509,683 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TruqapCapivasertib | 16 | $327,876 |
| KisqaliRibociclib Succinate | 18 | $243,526 |
| VerzenioAbemaciclib | 14 | $207,655 |
| TukysaTucatinib | 11 | $137,657 |
| Letrozole | 69 | $1,520 |
| Prochlorperazine Maleate | 30 | $507 |
| Ondansetron Hcl | 28 | $363 |
| Dexamethasone | 12 | $277 |
| Pregabalin | 15 | $258 |
| Tamoxifen Citrate | 12 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTruqap | $153,185 | $327,87616 claims |
| NovartisKisqali | $34,529 | $243,52618 claims |
| Lilly USA, LLCVerzenio | $15 | $207,65514 claims |
| Seagen Inc.Tukysa | $4,680 | $137,65711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 379 medical oncology providers in California.
Other medical oncology in Pasadena
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.